Vanguard Group Inc Uro Gen Pharma Ltd. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Vanguard Group Inc holds 284,437 shares of URGN stock, worth $2.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

284,437

Previous 223,982 26.99%

Holding current value

$2.91 Million

Previous $3.76 Million 3.89%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$12.7 - $17.92 $767,778 - $1.08 Million	60,455 Added 26.99%	284,437 $3.61 Million
Q2 2024 Aug 13, 2024	BUY	$12.72 - $19.2 $369,083 - $557,107	29,016 Added 14.88%	223,982 $3.76 Million
Q1 2024 May 10, 2024	BUY	$13.81 - $19.33 $336,508 - $471,014	24,367 Added 14.28%	194,966 $2.92 Million
Q4 2023 Feb 14, 2024	BUY	$10.87 - $15.93 $638,775 - $936,126	58,765 Added 52.55%	170,599 $2.56 Million
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $106,247 - $272,110	12,019 Added 12.04%	111,834 $1.57 Million
Q2 2023 Aug 14, 2023	BUY	$8.75 - $14.29 $873,381 - $1.43 Million	99,815 New	99,815 $1.03 Million
Q2 2022 Aug 12, 2022	SELL	$5.12 - $8.74 $545,116 - $930,530	-106,468 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.92 - $9.73 $1,468 - $2,413	-248 Reduced 0.23%	106,468 $927,000
Q4 2021 Feb 14, 2022	BUY	$9.03 - $19.13 $31,767 - $67,299	3,518 Added 3.41%	106,716 $1.02 Million
Q3 2021 Nov 12, 2021	BUY	$14.31 - $18.39 $97,708 - $125,566	6,828 Added 7.09%	103,198 $1.74 Million
Q2 2021 Aug 13, 2021	BUY	$15.2 - $20.94 $1.46 Million - $2.02 Million	96,370 New	96,370 $1.47 Million

Others Institutions Holding URGN

# of Institutions

130

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $233M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Uro Gen Pharma Ltd. Transaction History